Table 2.

Hazard of mortality in the sickle cell disease group compared with the controls

Treatment Modality	Model	Hazard Ratio (95% CI)
Dialysis	Model 1	1.21 (1.15 to 1.27)
	Model 2	1.48 (1.41 to 1.56)
	Model 3	2.14 (2.03 to 2.25)
Waiting list	Model 1	1.98 (1.75 to 2.23)
	Model 2	2.00 (1.78 to 2.26)
	Model 3	3.21 (2.84 to 3.62)
Post-transplant	Model 1	1.81 (1.45 to 2.27)
	Model 2	1.72 (1.38 to 2.16)
	Model 3	3.03 (2.42 to 3.80)

Model 1 was unadjusted. Model 2 restricted the non–sickle cell disease group to only those who were identified as Black or African American. Model 3 was adjusted for age, sex, comorbidities (hypertension, diabetes, heart disease, stroke, and current tobacco use), body mass index, hemoglobin, serum albumin, dialysis type, for-profit status of the dialysis center, and primary payer (dialysis mortality); age, sex, diabetes, body mass index, history of previous kidney transplant, and time from dialysis initiation to waitlist registration (waitlist mortality); and recipient factors (age at transplant, sex, diabetes, hypertension, body mass index, panel-reactive antibody, time on dialysis at transplant, serum albumin, peripheral vascular disease, malignancy, hepatitis C virus and hepatitis B virus seropositivity, previous kidney transplant, education level, primary payer, and number of HLA-A/B/DR mismatches), donor factors (age, sex, race, body mass index, hepatitis C virus seropositivity, diabetes, and hypertension), and additional factors for deceased donors (donation after cardiac death, stroke as the cause of donor death, terminal serum creatinine, and cold ischemic time) (post-transplant mortality). 95%, 95% confidence interval.